Self link
These are notes to
self, made available in hope they will attract tough comments, reveal my
directions and their reason; are not intended to hurt any views – I am a stoic,
perhaps buddhist, consider all not so to be noxious vermin, but see no reason
to propagate my views. Some people who can discern scholastic approach to
questions (hard stoic but not skeptic) requiring a rational conclusion for all
questions rangfing over UNinteresting to besides the point to sophistry if unrational,
Rational stoic (not a persistent skeptic!) to distance from pure scientist.
the fellows
referenced have a common theme
approach is
scientific path to amortality
consider empirical
studies on humans to be gold standard
are in possesion
of data on models
have narratives on
why applicable to humans
experiment on self
first
have reasons to
believbe they are honest
are not
commercially driven (OK after studies only)
hence can be
emulated pre-proof
Dr. Nir
Barzilai is the director of the Institute for Aging Research at the Albert
Einstein College of Medicine and the Director of the Paul F. Glenn Center for
the Biology of Human Aging Research and of the National Institutes of Health’s
(NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is
the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the
Departments of Medicine and Genetics, and member of the Diabetes Research
Center and of the Divisions of Endocrinology & Diabetes and Geriatrics.
Dr.
Barzilai’s research interests are in the biology and genetics of aging. One
focuses on the genetic of exceptional longevity, where we hypothesize and
demonstrated that centenarians have protective genes, which allows the delay of
aging or for the protection against age-related diseases. In a Program he is
leading we take full advantage of phenotypes, DNA, and cells from the Ashkenazi
Jewish families with exceptional longevity and the appropriate controls and his
group have established at Einstein (over 2600 samples of which ~670 are
centenarians) and discovered underling genomic differences associated with
longevity. Longevity Genes Project (LGP) is a cross-sectional, on-going
collection of blood and phenotype from families with centenarian proband.
LonGenity is a longitudinal study of 1400 subjects, half offspring of parents
with exceptional longevity, validating and following their aging in
relationship to their genome. The second direction, for which Dr. Barzilai is
holding an NIH Merit award that focuses on the metabolic decline of aging, and
his team hypothesize that the brain leads this decline. His lab has identified
several central pathways that specifically alter body fat distribution and
insulin action and secretion by intraventricular or hypothalamic administration
of several peptides that are modulated by aging including: Leptin, IGF-1,
IGFBP3 and resveratrol.
He has
received numerous grants, among them ones from the National Institute on Aging
(NIA), American Federation for Aging Research, the Ellison Medical Foundation
and The Glenn Medical foundation. He has published over 230 peer-reviewed
papers, reviews, and textbook chapters. He is an advisor to the NIH on several
projects and serves on several editorial boards and is a reviewer for numerous
other journals. Dr. Barzilai is in the board of the American Federation for
Aging Research, is its co-scientific director, and has served on several NIA
study section. He is also a founder of CohBar Inc., a biotech that develops
mitochondrial derived peptides as therapy for aging and its diseases. He is
co-PI on the R24 Geroscience (Apollo) grant that is an effort to move the field
of aging to translation. Dr. Barzilai has been the recipient of numerous
prestigious awards, including the Beeson Fellow for Aging Research, the Ellison
Medical Foundation Senior Scholar in Aging Award, the Paul F. Glenn Foundation
Award, the NIA Nathan Shock Award, and the 2010 Irving S. Wright Award of
Distinction in Aging Research.
He is
currently leading an international effort to approve drugs that can target
aging. Targeting Aging with METformin (TAME) is a specific study designed to
prove the concept that multi-morbidities of aging can be delayed by metformin,
working with the FDA to approve this approach which will serve as a template for
future efforts to delay aging and its diseases in humans.
Born in
Israel, Dr. Barzilai served as chief medic and physician in the Israel Defense
Forces. He graduated from The Ruth and Bruce Rappaport Faculty of Medicine at
the Technion-Israel Institute of Technology in Haifa and completed his
residency in internal medicine at Hadassah Medical Center in Jerusalem. He
served in a refugee camp during the war in Cambodia (1979-1980) and built a
nutritional village in the homeland of the Zulu (1983 – Kwazulu). He has
completed 2 fellowships at Yale (metabolism) and Corenell (Endocrinoology and
molecular Medicine). He was an invited speaker to the 4th Israeli President
Conference (2012) and a Vatican conference on efforts to enhance cures (2013,
2016). He has also taken part in Global initiatives and spoke at The Milken
Global Institute, Asian Megatrends and is an advisor for the Prime Minister of
Singapore on Aging. Dr. Barzilai has been on the ‘Forward 50, top 50 influence
Jews in the US (2011). His work has been profiled by major outlets, including
the New York Times, the BBC and PBS' NOVA science now, TEDx talk Science and is
the leading feature on the Ron Howard/Jonathan Silberberg/National Geographic
film about the Age of Aging.
Matt Kaeberlein (born 1971[1]) is an American biologist
and biogerontologist best
known for his research on evolutionarily conserved mechanisms of aging. He is
currently a Professor of Pathology at the University of Washington in
Seattle.
The major research focus
of James L. Kirkland, M.D., Ph.D., is the impact of cellular aging (senescence)
on age-related dysfunction and chronic diseases, especially developing methods
for removing these cells and alleviating their effects. Senescent cells
accumulate with aging and in such diseases as dementias, atherosclerosis,
cancers, diabetes and arthritis.
The goal of Dr.
Kirkland's current work is to develop methods to remove these cells to delay,
prevent, alleviate or partially reverse age-related chronic diseases as a group
and extend health span, the period of life free of disability, pain, dependence
and chronic disease.
Focus areas
·
Cellular senescence. Dr. Kirkland's team developed the
idea that removing senescent cells may enhance health span, partly based on the
observation that mice with mutations that increase life span have lower senescent
cell burden than normal mice, and that short-lived mice have more of these
cells. To test this idea, Dr. Kirkland and his team, in collaboration with
others at Mayo Clinic, eliminated senescent cells from genetically modified
mice, in which a drug-activated "suicide" gene was expressed only in
senescent cells. They found that this process enhanced health span, at least in
the context of an accelerated aging-like disease. This gave proof of principle
for the notion that clearing senescent cells with a drug in
non-genetically-modified individuals might be beneficial. They continue to work
on developing interventions that selectively target senescent cells.
·
Diabetes, other chronic diseases and cellular senescence. Diabetes and
obesity are associated with accumulation of senescent cells in fat and other
tissues. Dr. Kirkland's group is working on ways to reduce severity and
alleviate the complications of diabetes by clearing senescent cells or blocking
them from producing factors that cause or exacerbate dysfunction. Effects of
eliminating senescent cells or the factors they release are being investigated
on frailty and a range of other chronic disorders in Dr. Kirkland's laboratory
and with collaborators at Mayo and other institutions.
Significance to patient care
Dr. Kirkland's work is
important in developing methods to enhance health span and delay onset of the
chronic age-related diseases as a group, rather than one at a time. These
conditions, including diabetes, dementias, atherosclerosis, cancers and arthritis,
among others, account for the bulk of morbidity, mortality and health costs in
most of the world.
he Sinclair Lab studies
the processes that drive aging and age-related diseases, and works toward
discovering methods for slowing down or reversing these processes. Work ranges
from dissecting novel pathways and identifying target genes, to assessing small
molecules that may slow the pace of aging and increase healthspan. The overarching
goal is to establish new biological approaches that can be translated into
radically different medicines to promote longer, more productive lives. A focus
is on how genetic and epigenetic changes drive aging, common diseases and
disorders such as cancer, heart disease, inflammation, neurodegeneration,
infertility and diabetes. To advance our studies we use a wide range of
genetic, genomic and proteomic tools. In addition we employ several unique
mouse models to assess the role of these factors and how well genetic and
pharmacological agents may impact them. We are a team with a broad range of
skill sets, who work together and complement each other to solve key scientific
questions about mammalian biology and human health. Skills in the lab range from
enzymology and biochemistry, to genetics, genomics, proteomics and systems
biology.
Their recommendations
compress to two – metformin and NMN. I add a third - MITOQ. Here is my
reasoning – pointless to debate but med MD-PhD. ALL life is cellular, all animals
age. So aging is cellular – mitochondria based. MITOQ feeds COQ10 to Mitochondria
bypassing all, to be greatly bio-available. No wittig-like Carrier for NMN or
metformin. Metformin good for actual diabetic and aging pseudo-diabetics. Insulin
promotes aging as do high sugars! Sublingual administration of 500 mg of NMN
per day is twice the dose taken by Sinclair! Metformin is dirt cheap. MITOQ is
$1 per day, so is NMN. That plus NMN and exercise is to be given up, if no
benefits in 3 month. The drugs should enable you to do exercise! If you
attribute your health to exercise, don’t forget what enabled you!